Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment called BIIB080 for individuals with Mild Cognitive Impairment due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia. The treatment involves a special type of medication known as an antisense oligonucleotide, which is designed to target specific proteins in the brain that are associated with Alzheimer's disease. The study also uses a medication called Vizamyl, which is a solution for injection that helps in imaging the brain, and Neuraceq, another imaging agent. A placebo, which is an inactive substance, is also used for comparison.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer's disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer's disease.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes evaluating memory and cognitive abilities using specific tests.

    The assessment involves a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) test, which measures memory, and a Clinical Dementia Rating (CDR) test to assess cognitive function.

  2. Step 2

    Baseline visit

    A baseline visit is scheduled to establish initial health and cognitive status. This visit includes a physical examination and collection of medical history.

    During this visit, a lumbar puncture may be performed to collect cerebrospinal fluid for analysis.

  3. Step 3

    Treatment administration

    Participants receive the study medication, BIIB080, or a placebo through intrathecal use, which means it is injected into the spinal canal.

    The medication is administered at regular intervals as determined by the study protocol.

  4. Step 4

    Regular monitoring

    Participants attend regular visits to monitor health and cognitive function. These visits include physical exams and cognitive tests.

    Monitoring continues throughout the study to ensure safety and track any changes in symptoms.

  5. Step 5

    Imaging assessments

    Participants undergo imaging assessments using flutemetamol (18F) or florbetaben (18F) through intravenous injection to evaluate brain changes.

    These assessments help in understanding the effects of the treatment on brain structure and function.

  6. Step 6

    Final evaluation

    At the end of the study period, a final evaluation is conducted to assess overall health and cognitive changes.

    This includes repeating the initial assessments and comparing results to determine the treatment's effectiveness.

Who can join the trial?

12 criteria

  • Must have a diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer's Disease or mild Alzheimer's Disease dementia.
  • Must have a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Delayed Memory Index score of 85 or lower, which shows memory problems.
  • Must have a Clinical Dementia Rating (CDR) global score of 0.5 for MCI or 0.5 or 1 for mild dementia.
  • Must have a Mini-Mental State Examination (MMSE) score between 21 and 30.
  • Must have a CDR Memory Box score of 0.5 or higher.
  • Must show evidence of amyloid pathology, which is a protein related to Alzheimer's, through specific tests like PET scans or spinal fluid sampling.
  • Must be able to understand the study's purpose and risks, and provide consent, either personally or through a legal representative.
  • Must have completed the initial part of the study, including the Week 76 visit.
  • Must have taken at least 5 doses of the study medication or placebo during the initial study period.
  • Must be medically able to undergo study procedures, including a lumbar puncture (a procedure to collect spinal fluid), and follow the visit schedule.
  • Must be in good health apart from Alzheimer's Disease, as determined by the study doctor.
  • Must have a care partner who spends at least 10 hours per week with them and can provide information about their abilities.

Who cannot join the trial?

14 criteria

  • Patients with any other serious medical condition that might interfere with the study.
  • Patients who have had a recent major surgery or are planning to have surgery during the study period.
  • Patients who are currently participating in another clinical trial.
  • Patients with a history of severe allergic reactions to any medication.
  • Patients who are pregnant or breastfeeding.
  • Patients with a history of drug or alcohol abuse within the past year.
  • Patients who have been diagnosed with a psychiatric disorder that is not stable.
  • Patients who have a history of seizures or epilepsy.
  • Patients who have uncontrolled high blood pressure.
  • Patients who have a history of heart disease or stroke.
  • Patients who have a history of cancer within the past five years, except for certain types of skin cancer.
  • Patients who have a history of liver or kidney disease.
  • Patients who have a history of HIV or other immune system disorders.
  • Patients who are unable to comply with the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

BIIB080 is a medication being studied for its potential to help people with mild cognitive impairment or mild dementia due to Alzheimer's disease. This medication is designed to target and possibly slow down the progression of symptoms associated with Alzheimer's disease. The trial aims to understand how effective and safe BIIB080 is for patients, and how well it is tolerated over time. Participants in the study will receive this medication to see if it can improve their cognitive function and overall quality of life compared to those who do not receive it.

What is already known about the treatment

BIIB080 – BIIB080 is administered as an injection and is currently being studied in clinical trials to evaluate its effectiveness, safety, and tolerability for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. This medication is still under investigation, and its status in medical literature is primarily within the context of ongoing research. The main therapeutic indication for BIIB080 is to potentially slow down or improve symptoms associated with Alzheimer's disease. At the molecular level, BIIB080 is designed to target and reduce the accumulation of harmful proteins in the brain that are believed to contribute to the progression of Alzheimer's disease. It falls under the pharmacological classification of investigational drugs for neurodegenerative conditions.

Investigated diseases

  • Mild Cognitive Impairment due to Alzheimer's Disease

    This condition is characterized by a noticeable decline in cognitive abilities, such as memory and thinking skills, which is greater than expected for a person's age but does not interfere significantly with daily life. It is considered an early stage of Alzheimer's Disease, where individuals may experience forgetfulness, difficulty in finding words, or trouble with complex tasks. Over time, these cognitive changes may become more pronounced, potentially leading to more severe memory loss and confusion. The progression can vary, with some individuals maintaining stable symptoms for years, while others may progress to Alzheimer's Disease Dementia.

  • Alzheimer's Disease Dementia

    This is a progressive neurological disorder that leads to the degeneration of brain cells, resulting in memory loss and cognitive decline. It typically begins with mild memory lapses and confusion, gradually worsening to affect language, reasoning, and the ability to perform everyday activities. As the disease advances, individuals may experience significant memory loss, disorientation, and changes in behavior and personality. The progression of Alzheimer's Disease Dementia can lead to severe cognitive impairment, where individuals require full-time care and assistance with daily living.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-501644-15-01Protocol code247AD201Estimated enrolment416 patientsSponsorBiogen Idec Research Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.